Evidence map›Paper›PMID 40548197›Full record

ArticleBlood neoplasia2024

Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study.

Koji Nagafuji, Toshihiro Miyamoto, Tetsuya Eto, Tomohiko Kamimura, Koji Kato, Yasuhiko Miyazaki, Atsushi Wake, Kentaro Kohno, Ken Takase, Yutaka Imamura and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Koji NagafujiDepartment of Medicine, Kurume University School of Medicine, Kurume, Japan.
Toshihiro MiyamotoHematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Tomohiko KamimuraDepartment of Hematology, Hara Sanshin General Hospital, Fukuoka, Japan.
Koji KatoDepartment of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Yasuhiko MiyazakiDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Atsushi WakeDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Kawasaki, Japan.
Kentaro KohnoDepartment of Hematology and Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan.
Ken TakaseDepartment of Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Yutaka ImamuraDivision of Hematology, Our Lady of the Snow Social Medical Corporation St. Mary's Hospital, Kurume, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Kazuki TanimotoDepartment of Hematology and Oncology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Noriaki KawanoDepartment of Hematology, Miyazaki Prefectural Hospital, Miyazaki, Japan.
Toshiro KurokawaDepartment of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
Yukio KondoDepartment of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan.
Yoshikiyo ItoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Tomoaki FujisakiDepartment of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Junichi TsukadaDepartment of Hematology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Koji YonemotoDivision of Biostatistics, School of Health Sciences, Faculty of Medicine, University of The Ryukyus, Nishihara, Japan.
Toshinori HoriDepartment of Pediatrics, Aichi Medical University Hospital, Aichi, Japan.
Koichi AkashiDepartment of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enhanced utilization of native L-asparaginase (L-Asp) aims to improve treatment outcomes for adult patients with non-Philadelphia chromosome (Ph) acute lymphoblastic leukemia (ALL). In this measurable residual disease 2014 (MRD2014) study, we modified our protocol to include an augmented dose of native L-Asp. Compared with former MRD2008, the total dose of L-Asp was raised from 36 000 U/m

Identifiers

PMID40548197
PMCPMC12182846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.